SEARCH

SEARCH BY CITATION

Keywords:

  • bacteriophage Q beta;
  • genetic engineering;
  • hematologic agents;
  • heparin;
  • polycations;
  • viruses

Abstract

Thumbnail image of graphical abstract

Particles to the rescue! The construction of cationic amino acid motifs on the surface of bacteriophage Qβ by genetic engineering or chemical conjugation gives particles that are potent inhibitors of the anticoagulant action of heparin, which is a common anticlotting agent subject to clinical overdose.

Polyvalent interactions allow biological structures to exploit low-affinity ligand–receptor binding events to affect physiological responses. We describe here the use of bacteriophage Qβ as a multivalent platform for the display of polycationic motifs that act as heparin antagonists. Point mutations to the coat protein allowed us to generate capsids bearing the K16M, T18R, N10R, or D14R mutations; because 180 coat proteins form the capsid, the mutants provide a spectrum of particles differing in surface charge by as much as +540 units (K16M vs. D14R). Whereas larger poly-Arg insertions (for example, C-terminal Arg8) did not yield intact virions, it was possible to append chemically synthesized oligo-Arg peptides to stable wild-type (WT) and K16M platforms. Heparin antagonism by the particles was evaluated by using the activated partial thrombin time (aPTT) clotting assay; this revealed that T18R, D14R, and WT-(R8G2)95 were the most effective at disrupting heparin-mediated anticoagulation (>95 % inhibition). This activity agreed with measurements of ζ potential (ZP) and retention time on cation exchange chromatography for the genetic constructs, which distribute their added positive charge over the capsid surface (+180 and +360 for T18R and D14R relative to WT). The potent activity of WT-(R8G2)95, despite its relatively diminished overall surface charge is likely a consequence of the particle's presentation of locally concentrated regions with high positive charge density that interact with heparin's extensively sulfated domains. The engineered cationic capsids retained their ability to inhibit heparin at high concentrations and showed no anticlotting activity of the kind that limits the utility of antiheparin polycationic agents that are currently in clinical use.